

Company Overview

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. The addressable market may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going third party outcomes studies. Acasti may need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre's indications to this segment. Acasti's strategy is to commercialize CaPre in the U.S. and the company is pursuing development and distribution partnerships to market CaPre in major countries around the world.

Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

Sep 9 2019, 12:00 AM EDT

Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

Sep 4 2019, 12:00 AM EDT

Stock Overview

Symbol	ACST	Crescendo Communications, LLC
Exchange	Nasdaq	626 RXR Plaza
Market Cap	184.83m	Uniondale, NY 11566
Last Price	\$2.17	T: 212-671-1020
52-Week Range	\$0.52 - \$2.95	ACST@crescendo-ir.com

09/17/2019 04:00 PM EDT

Investor Relations

Management Team

Jan D'Alvise

President and CEO

Pierre Lemieux, Ph.D.

Chief Operating and Scientific Officer, Co-Founder

Brian Groch

Chief Commercial Officer

Jean-François Boily, CPA, CA

Vice-President, Finance

Acasti Pharma Inc.

545 Promenade du Centropolis
Suite 100, Laval
, Québec H7T 0A3
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.